Tag:

Actelion

Latest Headlines

Latest Headlines

Boosted by Opsumit, one-time target Actelion is ready to make its own deals

Actelion hasn't been too keen on becoming an M&A target lately. But if it's the one in the driver's seat? Bring on the deals, CFO André Muller says.

Surging Actelion is on the hunt for buyouts amid 'M&A frenzy'

Fueled by strong sales for its latest cardio drug and a promising pipeline, Switzerland's Actelion says it's on the lookout for acquisitions but remains wary of paying the big premiums that have become commonplace in pharma.

Actelion launches Phase III MS test for ponesimod

Buoyed by the success of its PAH franchise, Switzerland's Actelion says it has begun a Phase III study of its in-house drug ponesimod for multiple sclerosis.

Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears

Actelion has presented detailed data on the drug it hopes will cement its position in the pulmonary arterial hypertension market, Uptravi. The shock-free data drove a small uptick in Actelion's stock, but fell short of being the blockbuster-guaranteeing release some were hoping to see.

Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease

Rare disease specialist Genzyme talked up the results of a study published in  The Journal of the American Medical Association  concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.

It's back to basics in M&A, and that's a good thing, Actelion CEO says

At least one potential tax-inversion buyout target is pretty happy about the new deal-quashing rules: Actelion CEO Jean-Paul Clozel. In fact, he says, the slap at inversions is not just good for him and Actelion, but for the whole pharma industry.

Actelion working with PatientsLikeMe rare cancer community on outcome measure

PatientsLikeMe is continuing to expand its business into new areas. Having struck its first broad R&D collaboration with a biopharma earlier this year, the online patient network has now given Actelion access to its community to create a new health outcome measure for a rare cancer.

Touting a Q2 beat and strong Opsumit launch, Actelion CEO dismisses takeover chatter

In the wake of AbbVie's $55 billion purchase of Ireland's Shire, which should slash the company's tax rate by more than a third, analysts are abuzz over which foreign company will be next on Big Pharma's buy list. Among the targets: Switzerland-based Actelion.

Pharma peer pressure makes tax-friendly M&A targets the new must-have

Talk about peer pressure. First, a couple of U.S. drugmakers pull off trans-Atlantic deals that shift their official HQs and lower their tax rates. Next, some bigger names go for the same tax-inversion strategy. Now, investors want to know why every drugmaker isn't jumping in.

Could Actelion and Cipla be next on Big Pharma's M&A takeover list?

Switzerland's Actelion has been on a winning streak of late, charting better-than-expected clinical trial results and beating analysts' earnings expectations thanks to fast-growing sales of its new blood pressure treatment. It's no wonder, then, that the company is a perennial subject of takeover rumors. But CEO Jean-Paul Clozel isn't interested in entertaining any deal offers.